Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis

Dear Editor, Biosimilars of anti-TNF-a inhibitors have become a valid and usually less expensive alternative to their originator drugs [1]. [...]switching from originator to biosimilar drugs is an increasingly widespread approach because of the potential cost savings. [...]etanercept, both originato...

Full description

Saved in:
Bibliographic Details
Published in:BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy biopharmaceuticals, and gene therapy, 2021-07, Vol.35 (4), p.469-471
Main Authors: Piaserico, Stefano, Conti, Andrea, Messina, Francesco, Meneguzzo, Alberto, Odorici, Giulia, Bellinato, Francesco, Gisondi, Paolo
Format: Article
Language:English
Subjects:
Antibodies
Arthritis
Biological products
Biomedical and Life Sciences
Biomedicine
Cancer Research
Conflicts of interest
Disease
Etanercept
Immunogenicity
Molecular Medicine
Patients
Pharmacotherapy
Psoriasis
Research Letter
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dear Editor, Biosimilars of anti-TNF-a inhibitors have become a valid and usually less expensive alternative to their originator drugs [1]. [...]switching from originator to biosimilar drugs is an increasingly widespread approach because of the potential cost savings. [...]etanercept, both originator and biosimilar, has shown to be associated with a low risk of immunogenicity and the very infrequent ADA to etanercept are non-neutralizing [5]. [...]the EGALITY study on psoriatic patients showed that there are no effects on the production of ADA with multiple switches between GP2015 and Enbrel [6]. [...]biosimilars represent an important opportunity for earlier and equal access to biological treatment, reducing the growing pressure on health care budgets and being a viable treatment option for a larger number of patients.
ISSN:1173-8804
1179-190X
DOI:10.1007/s40259-021-00485-8